Critical Path Initiative

About Critical Path

The Critical Path Initiative is FDA's effort to stimulate and facilitate a national effort to modernize the scientific process through which a potential human drug, biological product, or medical device is transformed from a discovery or "proof of concept" into a medical product.  More

• Frequently Asked Questions

Critical Path Opportunities Reports

• Projects Receiving Critical Path Support in Fiscal Year 2008
• FDA's Sentinel Initiative
• Critical Path Opportunities Initiated During 2007
• Critical Path Opportunities for Generic Drugs
• More

Faces Behind Critical Path

• Collaboration cornerstone of CPI... Interview with Dr. Rachel Behrman
• Making Medical Products Better, Faster, and Cheaper
• Interview on Warfarin
• Janet Woodcock Commentary on Critical Path
• More

Articles and Presentations

• FDA's Proactive Role in the Development of an Artificial Pancreas for the Treatment of Diabetes Mellitus
• Developing new drugs for the treatment of drug resistant tuberculosis:  a regulatory perspective
• Bioinformatics Modernization and the Critical Path to Improved Benefit-Risk Assessment of Drugs
• More

Spotlight on CPI Projects

• Clinical Trials Transformation Initiative
• Drug Discovery Today Interviews CTTI
• CDRH Medical Device Fellowship Program
• News on Genetic Basis of Adverse Events
• MedWatch^Plus Update
• More

Upcoming Events

• ASTM Workshop, May 19, 2009
• Workshop June 1-2, FDA/ NHLBI/NSF Computer Methods for Cardiovascular Devices
• More

Multimedia

• More